AdvaMed
The Medtech Association

AdvaMedDx
Vital Insights | Transforming Care

1301 Pennsylvania Avenue, NW
Suite 400
Washington, D.C. 20004
P :: 202.783.8700
F :: 202.783.8750
W:: AdvaMed.org

March 11, 2026

Senate Committee on Health and Welfare
Vermont State House
115 State Street
Room 17
Montpelier, VT 05633

Re: S 154 – Support

Dear Chair Lyons, Vice Chair Gulick, and Members of the Committee:

On behalf of AdvaMed, the MedTech Association, we are writing in support of S 154: *An act relating to health insurance coverage for biomarker testing,* legislation that will improve patient outcomes by ensuring access to vital biomarker testing.

AdvaMed is the world's largest association representing the full spectrum of medical technology innovators and manufacturers. AdvaMedDx, a division of AdvaMed, represents over 80 manufacturers of *in vitro* diagnostic (IVDs) tests and technologies. Our member companies produce advanced IVD tests and technologies that allow early detection of disease, facilitate evidence-based medicine, improve patient and public health, and enable precision medicine. AdvaMedDx is the only advocacy organization exclusively addressing policy issues facing diagnostic manufacturers in the United States and abroad.

The significance of biomarker testing in patient care cannot be overstated. It is a game-changer in tailoring patient management and prevention plans by integrating individual medical histories and clinical symptoms. This approach is instrumental not just in cancer treatment but also across various medical fields like cardiology, neurology, infectious diseases, and autoimmune disorders. Conditions such as Alzheimer's Disease, Rheumatoid Arthritis, and Preeclampsia are just a few examples where biomarker testing can make a substantial difference.

Unfortunately, current health care coverage for biomarker testing is failing to keep pace with scientific advancements. S 154 aims to bridge this gap by requiring state-regulated health care plans to cover comprehensive biomarker testing when supported by medical and scientific evidence, including nationally recognized clinical practice guidelines. Timely access to appropriate biomarker testing will result in

better health outcomes, advance health equity, and reduce costs. For these reasons, AdvaMed strongly supports S 154.

Your support can transform the landscape of patient care. Thank you for your leadership on this critical healthcare initiative.

Sincerely,



Adrienne Frederick
Director, State Government & Regional Affairs
AdvaMed



Zach Rothstein
Executive Director
AdvaMedDx